RxDoctor Payments Data

Benjamin Pace, MD

Ophthalmology · Hattiesburg, MSNPI 1366853020

Payments from drug & device makers

What this record shows

Almost everything reported here is food and beverage — 100.0% of the total across 121 separate payments, which is the pattern of a clinician who attends manufacturer presentations rather than one with a consulting arrangement. 17 manufacturers reported payments, led by AbbVie at 49.4% of the total.

$2,623in general payments, 2019–2025

Across 121 payments — averaging $21.68 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • AbbVie$1K
  • Ocular Therapeutix, Inc.$273
  • Aerie Pharmaceuticals, Inc.$226
  • Alcon$221
  • Oyster Point Pharma, Inc.$103
  • Johnson & Johnson Surgical Vision, Inc.$101
  • plus $403 from 11 others

What the payments were for

  • Food & beverage$2,623100%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

19
20
21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

How this compares

$2,623 in reported general payments places this provider in the 60th percentile of 150 ophthalmology providers in Mississippi.

See all ophthalmology providers in Mississippi

Medicare billing

Part B allowed, 2024
$396,083
Medicare patients
1,110
Services billed
3,397

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
Prednisolone Acetate501$16,598
LumiganBimatoprost41$14,137
RestasisCyclosporine12$12,127
Ketorolac Tromethamine469$7,569
CombiganBrimonidine Tartrate/Timolol12$5,822
Brimonidine Tartrate88$5,282
Ofloxacin442$5,107
Latanoprost430$3,509
Dorzolamide-TimololDorzolamide Hcl/Timolol Maleat196$3,207
Travoprost28$2,372
ErythromycinErythromycin Base162$1,783
Timolol Maleate110$1,466
ValacyclovirValacyclovir Hcl31$994
Neomycin-Polymyxin-DexamethNeomycin/Polymyxin B/Dexametha69$758
Dorzolamide Hcl14$278

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
AbbVieLumigan, Restasis, Combigan$1,295$32,08665 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 60th percentile of 150 ophthalmology providers in Mississippi.

Other ophthalmology in Hattiesburg

See the full list for Mississippi

Where these figures come from

Is this you, or does something look wrong? →